Presentation is loading. Please wait.

Presentation is loading. Please wait.

Recombinant allergens: What does the future hold?

Published byRoland McKinney Modified over 6 years ago

Similar presentations

Presentation on theme: "Recombinant allergens: What does the future hold?"— Presentation transcript:

1 Recombinant allergens: What does the future hold?
Rudolf Valenta, MD, Katarzyna Niespodziana, MSc, Margit Focke-Tejkl, PhD, Katharina Marth, MD, Hans Huber, PhD, Angela Neubauer, PhD, Verena Niederberger, MD  Journal of Allergy and Clinical Immunology  Volume 127, Issue 4, Pages (April 2011) DOI: /j.jaci Copyright © 2011 American Academy of Allergy, Asthma & Immunology Terms and Conditions

2 Fig 1 From allergen-encoding DNA to recombinant allergen–based vaccines. Allergen portions constituting conformational IgE epitopes on wild-type allergens are indicated in red and green, with the remaining allergen sequence in black. In fusion proteins large parts of the allergen are replaced by a foreign carrier protein (blue). Journal of Allergy and Clinical Immunology  , DOI: ( /j.jaci ) Copyright © 2011 American Academy of Allergy, Asthma & Immunology Terms and Conditions

3 Fig 2 Currently ongoing development lines for recombinant allergen–based vaccines. NCT numbers identify the trials that are registered in the National Institutes of Health Clinical trial database ( DBPC, Double-blind, placebo-controlled; OC, open controlled; SCIT, subcutaneous immunotherapy; SLIT, sublingual immunotherapy. Journal of Allergy and Clinical Immunology  , DOI: ( /j.jaci ) Copyright © 2011 American Academy of Allergy, Asthma & Immunology Terms and Conditions

Download ppt "Recombinant allergens: What does the future hold?"

Similar presentations

Joint modeling of parentally reported and physician-confirmed wheeze identifies children with persistent troublesome wheezing Danielle C.M. Belgrave, MSc,

Joint modeling of parentally reported and physician-confirmed wheeze identifies children with persistent troublesome wheezing Danielle C.M. Belgrave, MSc,
Early exposure to cow's milk protein is protective against IgE-mediated cow's milk protein allergy Yitzhak Katz, MD, Nelly Rajuan, MSc, Michael R. Goldberg,

Early exposure to cow's milk protein is protective against IgE-mediated cow's milk protein allergy Yitzhak Katz, MD, Nelly Rajuan, MSc, Michael R. Goldberg,
Control of immunopathology during chikungunya virus infection Caroline Petitdemange, PhD, Nadia Wauquier, PhD, Vincent Vieillard, PhD Journal of Allergy.

Control of immunopathology during chikungunya virus infection Caroline Petitdemange, PhD, Nadia Wauquier, PhD, Vincent Vieillard, PhD Journal of Allergy.
Characteristics of childhood peanut allergy in the Australian Capital Territory, 1995 to 2007 Raymond James Mullins, MBBS, PhD, FRACP, FRCPA, Keith B.G.

Characteristics of childhood peanut allergy in the Australian Capital Territory, 1995 to 2007 Raymond James Mullins, MBBS, PhD, FRACP, FRCPA, Keith B.G.
Probiotics and prebiotic galacto-oligosaccharides in the prevention of allergic diseases: A randomized, double-blind, placebo-controlled trial  Kaarina.

Probiotics and prebiotic galacto-oligosaccharides in the prevention of allergic diseases: A randomized, double-blind, placebo-controlled trial  Kaarina.
Association of subcutaneous allergen-specific immunotherapy with incidence of autoimmune disease, ischemic heart disease, and mortality  Allan Linneberg,

Association of subcutaneous allergen-specific immunotherapy with incidence of autoimmune disease, ischemic heart disease, and mortality  Allan Linneberg,
Comparison of the immunogenicity of BM32, a recombinant hypoallergenic B cell epitope–based grass pollen allergy vaccine with allergen extract–based vaccines 

Comparison of the immunogenicity of BM32, a recombinant hypoallergenic B cell epitope–based grass pollen allergy vaccine with allergen extract–based vaccines 
Allergen immunotherapy: A practice parameter third update

Allergen immunotherapy: A practice parameter third update
A randomized, double-blind, placebo-controlled pilot study of sublingual versus oral immunotherapy for the treatment of peanut allergy  Satya D. Narisety,

A randomized, double-blind, placebo-controlled pilot study of sublingual versus oral immunotherapy for the treatment of peanut allergy  Satya D. Narisety,
Fatty acids, inflammation, and asthma

Fatty acids, inflammation, and asthma
Increased peanut-specific IgA levels in saliva correlate with food challenge outcomes after peanut sublingual immunotherapy  Michael Kulis, PhD, Katie.

Increased peanut-specific IgA levels in saliva correlate with food challenge outcomes after peanut sublingual immunotherapy  Michael Kulis, PhD, Katie.
Association of subcutaneous allergen-specific immunotherapy with incidence of autoimmune disease, ischemic heart disease, and mortality  Allan Linneberg,

Association of subcutaneous allergen-specific immunotherapy with incidence of autoimmune disease, ischemic heart disease, and mortality  Allan Linneberg,
Santa Jeremy Ono, BA, PhD, Mark B. Abelson, MD 

Santa Jeremy Ono, BA, PhD, Mark B. Abelson, MD 
Ann-Marie M. Schoos, MD, PhD, Jacob D

Ann-Marie M. Schoos, MD, PhD, Jacob D
Development and characterization of a recombinant, hypoallergenic, peptide-based vaccine for grass pollen allergy  Margarete Focke-Tejkl, PhD, Milena.

Development and characterization of a recombinant, hypoallergenic, peptide-based vaccine for grass pollen allergy  Margarete Focke-Tejkl, PhD, Milena.
Major rabbit allergen Ory c 3: What could be its possible role as a sensitizing agent in real life?  Gennaro Liccardi, MD, Antonello Salzillo, MD, Maria.

Major rabbit allergen Ory c 3: What could be its possible role as a sensitizing agent in real life?  Gennaro Liccardi, MD, Antonello Salzillo, MD, Maria.
Delineating the specificity of an IgE-encoding transcriptome

Delineating the specificity of an IgE-encoding transcriptome
Safety and efficacy of immunotherapy with the recombinant B-cell epitope–based grass pollen vaccine BM32  Verena Niederberger, MD, Angela Neubauer, PhD,

Safety and efficacy of immunotherapy with the recombinant B-cell epitope–based grass pollen vaccine BM32  Verena Niederberger, MD, Angela Neubauer, PhD,
Is 9 more than 2 also in allergic airway inflammation?

Is 9 more than 2 also in allergic airway inflammation?
Probiotics during the first 7 years of life: A cumulative risk reduction of eczema in a randomized, placebo-controlled trial  Marko Kalliomäki, MD, PhD,

Probiotics during the first 7 years of life: A cumulative risk reduction of eczema in a randomized, placebo-controlled trial  Marko Kalliomäki, MD, PhD,

Similar presentations

Ads by Google